Nicholas Valiante, PhD
Founder, Chief Scientific Officer, President
Dr. Valiante is a vaccine industry thought leader with deep experience in all aspects of vaccine design, development, and clinical testing. A veteran of Chiron, Novartis, GSK, Moderna, and Glyde Bio, he has advanced vaccines and therapeutics to clinic targeting infectious diseases, cancer, allergy, autoimmunity, and aging. Nick has led clinically successful scientific and technical teams across a multitude of vaccine and biopharma platforms with world-class expertise in mRNA vaccine development. At Chiron/Novartis/GSK Dr. Valiante rose to the level of Global Head of Immunology and Immunotherapy, where he pioneered mRNA technologies as vaccines and therapeutics. In 2015 he joined Moderna Therapeutics during their hyper-growth phase and built their personalized cancer vaccine (PCV) platform. Here, he exploited the unique advantages of mRNA to develop a best-in-class PCV in 2 years. As Chief Scientific Officer he brings an unparalleled depth and breadth of vaccine and mRNA development experience to the Innovac team.
Dr. Valiante holds a BA from Boston University in Evolutionary Biology, a PhD from the University of Pennsylvania, and received post-graduate training at Stanford University.